Pedro Dorado Hernández
AuthID: R-000-EQE
1
TITLE: Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms Full Text
AUTHORS: Dorado, P; Lopez Torres, E; Em Penas LLedo; Martinez Anton, J; LLerena, A;
PUBLISHED: 2013, SOURCE: PHARMACOGENOMICS JOURNAL, VOLUME: 13, ISSUE: 4
AUTHORS: Dorado, P; Lopez Torres, E; Em Penas LLedo; Martinez Anton, J; LLerena, A;
PUBLISHED: 2013, SOURCE: PHARMACOGENOMICS JOURNAL, VOLUME: 13, ISSUE: 4
2
TITLE: CYP2D6 and the severity of suicide attempts
AUTHORS: Eva M Penas Lledo; Hilario Blasco Fontecilla; Pedro Dorado; Concepcion Vaquero Lorenzo; Enrique Baca Garcia; Adrian Llerena;
PUBLISHED: 2012, SOURCE: PHARMACOGENOMICS, VOLUME: 13, ISSUE: 2
AUTHORS: Eva M Penas Lledo; Hilario Blasco Fontecilla; Pedro Dorado; Concepcion Vaquero Lorenzo; Enrique Baca Garcia; Adrian Llerena;
PUBLISHED: 2012, SOURCE: PHARMACOGENOMICS, VOLUME: 13, ISSUE: 2
INDEXED IN: 
Scopus 
WOS
Scopus WOS3
TITLE: CYP2D6 and the severity of suicide attempts
AUTHORS: Eva M Peñas-Lledó; Hilario Blasco-Fontecilla; Pedro Dorado; Concepción Vaquero-Lorenzo; Enrique Baca-García; Adrián Llerena;
PUBLISHED: 2012, SOURCE: Pharmacogenomics, VOLUME: 13, ISSUE: 2
AUTHORS: Eva M Peñas-Lledó; Hilario Blasco-Fontecilla; Pedro Dorado; Concepción Vaquero-Lorenzo; Enrique Baca-García; Adrián Llerena;
PUBLISHED: 2012, SOURCE: Pharmacogenomics, VOLUME: 13, ISSUE: 2
INDEXED IN: 
CrossRef
CrossRef4
TITLE: Relevance of CYP2D6 for risperidone pharmacokinetics, pharmacodynamics and adverse reactions
AUTHORS: Adrian LLerena; Pedro Dorado; Eva M Penas LLedo;
PUBLISHED: 2011, SOURCE: PHARMACOGENOMICS, VOLUME: 12, ISSUE: 3
AUTHORS: Adrian LLerena; Pedro Dorado; Eva M Penas LLedo;
PUBLISHED: 2011, SOURCE: PHARMACOGENOMICS, VOLUME: 12, ISSUE: 3
INDEXED IN: WOS
WOS5
TITLE: Relevance of CYP2D6-1584C > G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients
AUTHORS: Pedro Dorado; Eva M Penas Lledo; Alfredo de la Rubia; Adrian Llerena;
PUBLISHED: 2009, SOURCE: PHARMACOGENOMICS, VOLUME: 10, ISSUE: 7
AUTHORS: Pedro Dorado; Eva M Penas Lledo; Alfredo de la Rubia; Adrian Llerena;
PUBLISHED: 2009, SOURCE: PHARMACOGENOMICS, VOLUME: 10, ISSUE: 7
6
TITLE: Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
AUTHORS: Eva M Penas Lledo; Pedro Dorado; Rodrigo Pacheco; Idilio Gonzalez; Adrian Llerena;
PUBLISHED: 2009, SOURCE: PHARMACOGENOMICS, VOLUME: 10, ISSUE: 7
AUTHORS: Eva M Penas Lledo; Pedro Dorado; Rodrigo Pacheco; Idilio Gonzalez; Adrian Llerena;
PUBLISHED: 2009, SOURCE: PHARMACOGENOMICS, VOLUME: 10, ISSUE: 7
INDEXED IN: Scopus WOS
Scopus WOS7
TITLE: Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers
AUTHORS: Eva M Peñas-LLedó; Pedro Dorado; Rodrigo Pacheco; Idilio González; Adrián LLerena;
PUBLISHED: 2009, SOURCE: Pharmacogenomics, VOLUME: 10, ISSUE: 7
AUTHORS: Eva M Peñas-LLedó; Pedro Dorado; Rodrigo Pacheco; Idilio González; Adrián LLerena;
PUBLISHED: 2009, SOURCE: Pharmacogenomics, VOLUME: 10, ISSUE: 7
INDEXED IN: CrossRef
CrossRef8
TITLE: Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms
AUTHORS: Enrique Lopez Torres; Jesus Salomon; Francis Vicario; Eva Penas LLedo; Pedro Dorado; Adrian Llerena;
PUBLISHED: 2008, SOURCE: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, VOLUME: 28, ISSUE: 3
AUTHORS: Enrique Lopez Torres; Jesus Salomon; Francis Vicario; Eva Penas LLedo; Pedro Dorado; Adrian Llerena;
PUBLISHED: 2008, SOURCE: JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, VOLUME: 28, ISSUE: 3
INDEXED IN: Scopus WOS
Scopus WOS9
TITLE: CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits
AUTHORS: Pedro Dorado; Eva M Penas LLedo; Adrian LLerena;
PUBLISHED: 2007, SOURCE: PHARMACOGENOMICS, VOLUME: 8, ISSUE: 11
AUTHORS: Pedro Dorado; Eva M Penas LLedo; Adrian LLerena;
PUBLISHED: 2007, SOURCE: PHARMACOGENOMICS, VOLUME: 8, ISSUE: 11
10
TITLE: No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients Full Text
AUTHORS: Pedro Dorado; Roland Berecz; Eva M Penas Lledo; Alfredo de la Rubia; Adrian LLerena;
PUBLISHED: 2007, SOURCE: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, VOLUME: 63, ISSUE: 5
AUTHORS: Pedro Dorado; Roland Berecz; Eva M Penas Lledo; Alfredo de la Rubia; Adrian LLerena;
PUBLISHED: 2007, SOURCE: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, VOLUME: 63, ISSUE: 5
